101-150

Which substituent of chloramphenicol is responsible for its toxic effect? a. The nitro group b. The 2 alcohol groups c. The dichloroacetamide group d. The aromatic ring e. A and B only

Which of the following statements is correct regarding Erythromycin? I. Erythromycin binds to the 50s subunit of bacterial ribosomes II. When administered together with chloramphenicol, their bacteriostatic effect will increase. III. The ketone and 2 alcohol groups in its structure are responsible for its acid sensitivity. IV. Increasing the size of the macrocycle to a 16 membered ring can increase the acid stability of the molecule.

Amantadine is one of the earliest antiviral drugs used clinically against flu. Which of the following statements is correct regarding amantadine? I. Amantadine is an adamantine related to rimantadine. II. It inhibits the penetration and uncoating of the influenza virus. III. It can inhibit replication of the influenza virus by blocking a viral ion channel called matrix (M2) protein IV. At high concentrations, it can alter pH of endosomes and prevent the acidic environment required by the hemagglutinins to fuse the viral membrane with that of the endosome.

Which among the given structures can be intercalating agent which can slide between the base pairs of the DNA double helix and thereby can inhibit the enzymes involved in the replication and transcription processes? a. Structure I b. Structure II c. Structure III d. Structure IV e. II and III

Which among the given structures is an antimetabolite that can inhibit the enzymes involved in the synthesis of DNA or its nucleotide building blocks? a. Structure I b. Structure II c. Structure III d. Structure IV e. II and III

Which of the given structures can form strong covalent bonds with the nucleophilic groups on DNA which can eventually result to cross-linking of strands? a. Structure I b. Structure II c. Structure III d. Structure IV e. II and III

Which of the given structures can be classified as an alkylating agent? a. Structure I b. Structure II c. Structure III d. Structure IV e. II and III

A semi-synthetic analogue of camptothecin given intravenously and is a prodrug used in combination with fluorouracil and folinic acid for the treatment of advanced colorectal cancer. a. Oblimersen b. Calicheamicin c. Carboplatin d. Irinotecan e. Cyclophosphamide

An antisense drug designed to inhibit the mRNA molecules that code for proteins which suppress apoptosis. a. Oblimersen b. Calicheamicin c. Carboplatin d. Irinotecan e. Cyclophosphamide

A natural product that reacts with nucleophiles to produce diradical species. Its reaction with DNA ultimately leads to cutting of the DNA chains. a. Oblimersen b. Calicheamicin c. Carboplatin d. Irinotecan e. Cyclophosphamide

It is the most commonly used alkylating agent in cancer chemotherapy, the metabolism of which produces arcolein which is toxic to the bladder and kidneys. a. Oblimersen b. Calicheamicin c. Carboplatin d. Irinotecan e. Cyclophosphamide

An alkylating agent that can cause intrastrand cross-linking preferred over cisplatin for the intravenous treatment of advanced ovarian tumors because of its less severe side effects. a. Oblimersen b. Calicheamicin c. Carboplatin d. Irinotecan e. Cyclophosphamide

Which of the following drugs is not an alkylating agent used in cancer chemotherapy? a. Carmustine b. Busulfan c. Procarbazine d. Mitomycin C e. None of the choices

A thiopurine prodrug which is converted to its corresponding monophosphate that inhibits purine synthesis. a. Methotrexate b. 5-fluorouracil c. 6-mercaptopurine d. Pentostatin e. Cytarabine

An antimetabolite that is very similar in structure to the natural folates differing only in additional amino and methyl groups. It inhibits the enzyme dihydrofolate reductase which is responsible in maintaining levels of the enzyme cofactor tetrahydrofolate. a. Methotrexate b. 5-fluorouracil c. 6-mercaptopurine d. Pentostatin e. Cytarabine

This drug acts as a prodrug for a suicide inhibitor. It is converted in the body to the fluorinated analogue of 2’deoxyuridylic acid monophosphate which then combines with the enzyme thymidylate synthase and the cofactor. a. Methotrexate b. 5-fluorouracil c. 6-mercaptopurine d. Pentostatin e. Cytarabine

An anti-leukemia drug isolated from Streptomyces antibioticus and is a powerful inhibitor of Adenosine deaminase. a. Methotrexate b. 5-fluorouracil c. 6-mercaptopurine d. Pentostatin e. Cytarabine

A prodrug analogue of 2’deoxycytidine which inhibits DNA polymerases. a. Methotrexate b. 5-fluorouracil c. 6-mercaptopurine d. Pentostatin e. Cytarabine

Which of the following pairs is correctly matched? I. Glucocorticoids: Megestrol acetate II. Progestins: prednisone III. Estrogens: Diethylstilbestrol IV. Androgens: Fluoxymesterone

A decapeptide analogue of the luteinizing hormone – releasing hormone designed to be more resistant to peptidase degradation. a. Goserelin b. Raloxifene c. Cyproterone acetate d. Anastrazole e. 4-hydroxyandrostenedione

A reversible competitive inhibitor of the enzyme aromatase , the design of which is based on structure of amino gluthetimide. a. Goserelin b. Raloxifene c. Cyproterone acetate d. Anastrazole e. 4-hydroxyandrostenedione

This mode of therapy involves an antibody which has catalytic activity designed to activate a prodrug. a. Antibody-directed enzyme prodrug therapy (ADEPT) b. Antibody-directed abzyme prodrug therapy (ADAPT) c. Gene-directed enzyme prodrug therapy (GDEPT) d. Photodynamic therapy e. All of the above

This mode of therapy involves the delivery of a gene that codes for an enzyme capable of activating an anticancer prodrug into a cancer cell. a. Antibody-directed enzyme prodrug therapy (ADEPT) b. Antibody-directed abzyme prodrug therapy (ADAPT) c. Gene-directed enzyme prodrug therapy (GDEPT) d. Photodynamic therapy e. All of the above

This involves irradiation of tumors containing porphyrin photosensitizers resulting to the production of reactive oxygen species which are fatal to the cell. a. Antibody-directed enzyme prodrug therapy (ADEPT) b. Antibody-directed abzyme prodrug therapy (ADAPT) c. Gene-directed enzyme prodrug therapy (GDEPT) d. Photodynamic therapy e. All of the above